BSG and COVID-19: Combined with the fact that not only several groups have revealed the promise of targeting CD147 as a potential therapy for COVID-19, but also niclosamide has been proven its high efficacy against SARS-CoV-259, plus its suppression on fibrosis38, these results demonstrate a new mechanism for niclosamide to aid the COVID-19 disease progression.